Literature DB >> 2705794

Value of selective screening for congenital adrenal hyperplasia in Hungary.

J Sólyom1, I A Hughes.   

Abstract

Measurement of the 17-hydroxyprogesterone concentration in blood spots was used to identify cases of congenital adrenal hyperplasia among patients with inappropriate virilisation, or salt wasting, or both. Between 1978 and 1986 61 were identified among 707 patients (278 neonates, 204 infants, and 225 children). The incidence of classic congenital adrenal hyperplasia was calculated for a seven year prospective trial period using the blood spot 17-hydroxyprogesterone method in selective screening. There were 38 salt losers and 14 simple virilisers in 968,303 live births, an incidence of congenital adrenal hyperplasia of 1:18,000 in the Hungarian population. Selective screening led to earlier diagnosis of congenital adrenal hyperplasia and a pronounced decrease in mortality. A central laboratory to measure the blood spot 17-hydroxyprogesterone concentrations is valuable for the investigation of patients at risk for congenital adrenal hyperplasia in countries where blood steroid assays are not readily available.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2705794      PMCID: PMC1791938          DOI: 10.1136/adc.64.3.338

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  18 in total

1.  Early diagnosis of congenital adrenal hyperplasia by measurement of 17-hydroxyprogesterone.

Authors:  E Youssefnejadian; R David
Journal:  Clin Endocrinol (Oxf)       Date:  1975-07       Impact factor: 3.478

2.  The incidence of congenital adrenal hyperplasia in Switzerland--a survey of patients born in 1960 to 1974.

Authors:  E A Werder; R E Siebenmann; G Knorr-Mürset; A Zimmermann; P C Sizonenko; P Theintz; J Girard; M Zachmann; A Prader
Journal:  Helv Paediatr Acta       Date:  1980-03

3.  Plasma 17-hydroxyprogesterone concentrations in ill newborn infants.

Authors:  J F Murphy; B G Joyce; J Dyas; I A Hughes
Journal:  Arch Dis Child       Date:  1983-07       Impact factor: 3.791

Review 4.  Congenital and acquired disorders of the adrenal cortex.

Authors:  I A Hughes
Journal:  Clin Endocrinol Metab       Date:  1982-03

5.  A pilot newborn screening for congenital adrenal hyperplasia in Alaska.

Authors:  S Pang; W Murphey; L S Levine; D A Spence; A Leon; S LaFranchi; A S Surve; M I New
Journal:  J Clin Endocrinol Metab       Date:  1982-09       Impact factor: 5.958

6.  Plasma 17OH-progesterone concentrations in newborn infants.

Authors:  I A Hughes; D Riad-Fahmy; K Griffiths
Journal:  Arch Dis Child       Date:  1979-05       Impact factor: 3.791

7.  A method for identification and follow-up of patients with a steroid-21-hydroxylase deficiency.

Authors:  J Sólyom; G L Hammond; R Vihko
Journal:  Clin Chim Acta       Date:  1979-03-01       Impact factor: 3.786

8.  Blood spot glucocorticoid concentrations in ill preterm infants.

Authors:  D Hughes; J F Murphy; J Dyas; J A Robinson; D Riad-Fahmy; I A Hughes
Journal:  Arch Dis Child       Date:  1987-10       Impact factor: 3.791

9.  Congenital adrenal hyperplasia--a clinical and genetic survey. Are we detecting male salt-losers?

Authors:  L Murtaza; J R Sibert; I Hughes; I C Balfour
Journal:  Arch Dis Child       Date:  1980-08       Impact factor: 3.791

10.  "Dot-17 alpha-hydroxyprogesterone" radioimmunoassay for identification of congenital adrenal hyperplasia in young infants.

Authors:  J Sólyom; S Hervei; P Marossy; E Sólyom; M Babosa; G Szombathy
Journal:  Acta Paediatr Scand       Date:  1981-11
View more
  1 in total

1.  Twenty years experience in rapid identification of congenital adrenal hyperplasia in Hungary.

Authors:  Dóra Török; Gudrun Eckhardt; János Sólyom
Journal:  Eur J Pediatr       Date:  2003-09-30       Impact factor: 3.183

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.